IL17A and metabolic dysfunction-associated steatotic liver disease: Empagliflozin has also been reported to significantly enhance autophagy in hepatic macrophages through the AMPK/mTOR pathway, suppressing the IL-17/IL-23 axis and improving liver injury related to NAFLD (163).